|
Mar 14
|
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
|
|
Feb 24
|
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
|
|
Feb 24
|
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
|
|
Feb 23
|
Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
|
|
Feb 22
|
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
|
|
Feb 19
|
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
|
|
Feb 19
|
Challenges mount for vaccine makers
|
|
Feb 19
|
Press Release: Sanofi and CD&R sign Opella share purchase agreement
|
|
Feb 18
|
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
|
|
Feb 18
|
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
|
|
Feb 18
|
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
|
|
Feb 7
|
Sanofi increases ownership stake partaking in pharma buyback trend
|
|
Feb 7
|
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
|
|
Feb 7
|
Press Release: Execution of a share buyback agreement for up to €2 billion
|
|
Feb 5
|
Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now
|
|
Feb 5
|
Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call
|
|
Feb 4
|
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend
|
|
Feb 4
|
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
|